Dr. Thomas Dayspring Joins Foundation for Health Improvement and Technology (FHIT)
RICHMOND, Va., March 21, 2012 /PRNewswire/ — Foundation for Health Improvement and Technology (FHIT), www.fhit.org, announced today that Thomas Dayspring, MD, FACP, FNLA, NCMP, has been named Director of Cardiovascular Education for the newly launched, national nonprofit.
“Joining FHIT will allow me to continue my life’s work dedicated to ridding the world of preventable cardiovascular and related metabolic diseases,” said Dr. Dayspring. “By offering a new level of educational programs across the United States, FHIT will promote early detection, aggressive medical treatment, and the latest scientific developments in cardiovascular and related diseases.”
Dr. Dayspring is a Diplomat of both the American Board of Internal Medicine and American Board of Clinical Lipidology. He is a Clinical Assistant Professor of Medicine at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School and Dr. Dayspring has operated a private medical practice for over 37 years, while concentrating on patients with complex lipid disorders.
“There is no better leader in the fight against cardiovascular disease than Dr. Tom Dayspring, and his list of medical teaching credentials is endless and without comparison,” said Russ Warnick, co-founder of FHIT. Dr. Dayspring is a Fellow of the American College of Physicians, a Fellow of the National Lipid Association and a certified menopause practitioner by the North American Menopause Society. In 2011 he was awarded the National Lipid Association President’s Award for his contributions to clinical lipidology. He is listed in the Guide to America’s Top Physicians, serves on the Editorial Board of the Journal of Clinical Lipidology, and he interacts with many other medical organizations.
Dr. Dayspring, who is one of the most requested speakers in the United States, will bring to FHIT extensive expertise on atherothrombosis, lipoprotein and vascular biology, advanced biomarker testing, and the CV effects of estrogen and selective estrogen receptor modulation. Dr. Dayspring has given over 4000 lectures, including over 500 hospital and medical school grand rounds, and large CME programs in all 50 states. He is the author of several book chapters on lipids as well as numerous peer-reviewed articles relating to lipids and lipoproteins and lipid-modulating medications.
Dr. Dayspring will utilize the unique educational aspects of FHIT to help physicians better understand and detect at an earlier stage of life risk factors that pre-dispose patients to cardiovascular and metabolic diseases such as diabetes.